Author:
Dutra Roberta Lelis,dos Santos Marcelo,Mendes Suzanny Oliveira,Peterle Gabriela Tonini,Louro Iúri Drumond,da Silva Conforti Adriana Madeira Álvares
Reference66 articles.
1. Acevedo VD, Ittmann M, Spencer DM. Paths of FGFR-driven tumorigenesis. Cell Cycle. 2009;8(4):580–8.
2. Ansell A, Farnebo L, Grenman R, et al. Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer. Oral Oncol. 2009;45:23–9.
3. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695–709.
4. Azad AK, Bairati I, Samson E, Cheng D, Mirshams M, Qiu X, Savas S, Waldron J, Wang C, Goldstein D, Xu W, Meyer F, Liu G. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival. Clin Cancer Res. 2012;18(1):196–206.
5. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002;62:840–7.